Restricted accessResearch articleFirst published online 2020-10
Effect of Pomegranate Extract in Mesenchymal Stem Cells by Modulation of microRNA-155,microRNA-21,microRNA-23b,microRNA-126a,and PI3K\AKT1\NF- κ B Expression
Today, mesenchymal stem cells (MSCs) are candidates for various autoimmune disease treatments due to immunomodulatory activity in these cells. Much research has recently been done to improve the immunomodulatory activity of MSCs. Genetic variation is one of these methods. microRNAs (miRNAs) are small noncoding RNAs that control most of the cell's biological activities. Recent studies have shown that miRNAs play a significant role in the regulation of MSC immunomodulatory activity. Pomegranate is a fruit that has antioxidant, anti-inflammatory, and anticancer properties and has been used for many years for therapeutic purposes. The objective of this research is to evaluate the immunoregulatory-related miRNAs level of adipose-derived MSCs (Ad-MSCs) obtained from adipose tissue in the presence or lack of pomegranate (Punica granatum) extract (PGE). Our results showed that miRNA-23 and miRNA-126 were upregulated by PGE treatment in MSCs, and in contrast, miRNA-21 and miRNA-155 were downregulated by PGE treatment in MSCs. In addition this research shows that PGE can downregulate the expression of PI3K\AKT1\NF-B in Ad-MSCs. Our bioinformatics data have shown that the target of these four miRNAs and the signaling pathways, in which these targets are involved, can play an important role in regulating the immunomodulation function of stem cells. In conclusion, PGE can inhibit the expression of PI3K\AKT1\NF-B genes involved in inflammatory pathways via miRNA-23 and miRNA-126 overexpression or miRNA-21 and miRNA-155 downregulation that plays a role in the pathways of immune modulation in Ad-MSCs. These results may provide insight into the mechanism underlying the regulation of the immunomodulatory activity of Ad-MSCs by PGE.
Get full access to this article
View all access options for this article.
References
1.
AchrafA., HamdiC., TurkiM., AbdelkarimO., AyadiF., HoekelmannA., et al. (2018). Natural pomegranate juice reduces inflammation, muscle damage and increase platelets blood levels in active healthy Tunisian aged men. Alexandria J Med, 54, 45–48.
2.
AggarwalS., and PittengerM.F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105, 1815–1822.
3.
AmbrosV. (2003). MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell, 113, 673–676.
4.
BaltimoreD., BoldinM.P., O'connellR.M., RaoD.S., and TaganovK.D. (2008). MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9,839.
5.
BanerjeeN., KimH., TalcottS., and Mertens-TalcottS. (2013). Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrant crypt foci and inflammation: possible role of miR-126/VCAM-1 and miR-126/PI3K/AKT/mTOR. Carcinogenesis, 34, 2814–2822.
6.
BanerjeeN., TalcottS., SafeS., and Mertens-TalcottS.U. (2012). Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation. Breast Cancer Res Treat, 136, 21–34.
7.
BhondeR.R., SheshadriP., SharmaS., and KumarA. (2014). Making surrogate β-cells from mesenchymal stromal cells: perspectives and future endeavors. The Int J Biochem Cell Biol, 46, 90–102.
8.
Castro-ManrrezaM.E., and MontesinosJ.J. (2015). Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res 2015,394917.
9.
ChenE.Y., TanC.M., KouY., DuanQ., WangZ., MeirellesG.V., et al. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics, 14,128.
10.
ChenQ., LiY., ChenZ., DuH., and WanJ. (2019). Anti-VCAM 1 antibody-coated mesenchymal stromal cells attenuate experimental colitis via immunomodulation. Med Sci Monit, 25, 4457–4468.
11.
ChiY., CuiJ., WangY., DuW., ChenF., LiZ., et al. (2016). Interferon-γ alters the microRNA profile of umbilical cord-derived mesenchymal stem cells. Mol Med Rep, 14, 4187–4197.
12.
CooperG.S., BynumM.L., and SomersE.C. (2009). Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun, 33, 197–207.
13.
DjouadF., FritzV., ApparaillyF., Louis-PlenceP., BonyC., SanyJ., et al. (2005). Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor α in collagen-induced arthritis. Arthritis Rheum, 52, 1595–1603.
14.
DorronsoroA., Fernández-RuedaJ., FechterK., FerrinI., SalcedoJ.M., JakobssonE., et al. (2013). Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications. Bone Marrow Res 2013,203643.
15.
EbrahimiA., and RahimF. (2014). Recent immunomodulatory strategies in transplantation. Immunol Invest, 43, 829–837.
16.
ElmanJ.S., LiM., WangF., GimbleJ.M., and ParekkadanB. (2014). A comparison of adipose and bone marrow-derived mesenchymal stromal cell secreted factors in the treatment of systemic inflammation. J Inflamm 11,1.
Garcia-OlmoD., Garcia-ArranzM., and HerrerosD. (2008). Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther, 8, 1417–1423.
21.
Garcia-OlmoD., HerrerosD., PascualI., PascualJ.A., Del-ValleE., ZorrillaJ., et al. (2009). Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rect, 52, 79–86.
22.
HouR., LiuR., ZhaoX., JiaY., AnP., HaoZ., et al. (2016). Increased miR-155-5p expression in dermal mesenchymal stem cells of psoriatic patients: comparing the microRNA expression profile by microarray. Genet Mol Res, 15. DOI: 10.4238/gmr.15038631
23.
JiangY., JahagirdarB.N., ReinhardtR.L., SchwartzR.E., KeeneC.D., Ortiz-GonzalezX.R., et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418,41.
24.
KarachiA., FazeliM., KarimiM.H., GeramizadehB., MoravejA., EbrahimnezhadS., et al. (2015). Evaluation of immunomodulatory effects of mesenchymal stem cells soluble factors on miR-155 and miR-23b expression in mice dendritic cells. Immunol Invest, 44, 427–437.
25.
KhorashadizadehM., SoleimaniM., KhanahmadH., FallahA., NaderiM., and KhorramizadehM. (2015). Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle. Tumor Biol, 36, 4213–4221.
26.
KhosraviM., KarimiM.H., AghdaieM.H., KalaniM., NaserianS., and BidmeshkipourA. (2017). Mesenchymal stem cells can induce regulatory T cells via modulating miR-126a but not miR-10a. Gene, 627, 327–336.
27.
KuoY.-R., ChenC.-C., GotoS., HuangY.-T., WangC.-T., TsaiC.-C., et al. (2012). Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One 7,e35459.
28.
Le BlancK., RasmussonI., SundbergB., GötherströmC., HassanM., UzunelM., et al. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363, 1439–1441.
29.
LiP., ZhengY., and ChenX. (2017). Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 8,460.
30.
LindsayM.A. (2008). microRNAs and the immune response. Trends Immunol, 29, 343–351.
31.
LiuM., and HanZ.C. (2008). Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy. J Cell Mol Med, 12, 1155–1168.
32.
MorandoS., VigoT., EspositoM., CasazzaS., NoviG., PrincipatoM.C., et al. (2012). The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res Ther 3,3.
33.
O'connellR.M., RaoD.S., ChaudhuriA.A., and BaltimoreD. (2010). Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10,111.
34.
OnoderaY., TeramuraT., TakeharaT., OboraK., MoriT., and FukudaK. (2017). miR-155 induces ROS generation through downregulation of antioxidation-related genes in mesenchymal stem cells. Aging Cell, 16, 1369–1380.
35.
PanthN., ManandharB., and PaudelK.R. (2017). Anticancer activity of Punica granatum (pomegranate): a review. Phytother Res, 31, 568–578.
36.
PhinneyD.G., and ProckopD.J. (2007). Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—Current views. Stem Cells, 25, 2896–2902.
37.
PittengerM.F., MackayA.M., BeckS.C., JaiswalR.K., DouglasR., MoscaJ.D., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143–147.
38.
RasmussonI., RingdénO., SundbergB., and Le BlancK. (2005). Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res, 305, 33–41.
39.
RenG., ZhangL., ZhaoX., XuG., ZhangY., RobertsA.I., et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2, 141–150.
40.
ShiM., LiuZ.W., and WangF.S. (2011). Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol, 164, 1–8.
41.
ShiY., HuG., SuJ., LiW., ChenQ., ShouP., et al. (2010). Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20,510.
42.
Vega-AvilaE., and PugsleyM.K. (2011). An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. Proc West Pharmacol Soc, 54, 10–14.
43.
VyseT.J., and ToddJ.A. (1996). Genetic analysis of autoimmune disease. Cell, 85, 311–318.
44.
WaldnerM., ZhangW., JamesI.B., AllbrightK., HavisE., BlileyJ.M., et al. (2018). Characteristics and immunomodulating functions of adipose-derived and bone marrow-derived mesenchymal stem cells across defined human leukocyte antigen barriers. Front Immunol 9,1642.
45.
WangD., ZhangH., LiangJ., LiX., FengX., WangH., et al. (2013). Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transpl, 22, 2267–2277.
46.
WangL., AlconA., YuanH., HoJ., LiQ.-J., and Martins-GreenM. (2011). Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol, 3, 742–754.
47.
WangY., ZhangA., YeZ., XieH., and ZhengS. (2009). Bone marrow–derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant Proc, 41, 4352–4356.
48.
WilliamT.T., PendletonJ.D., BeyerW.M., EgalkaM.C., and GuinanE.C. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 75, 389–397.
49.
WillisG.R., Fernandez-GonzalezA., AnastasJ., VitaliS.H., LiuX., EricssonM., et al. (2018). Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med, 197, 104–116.
50.
WuJ., JiC., CaoF., LuiH., XiaB., and WangL. (2017). Bone marrow mesenchymal stem cells inhibit dendritic cells differentiation and maturation by microRNA-23b. Biosci Rep 37,BSR20160436.
51.
WuT., LiuY., FanZ., XuJ., JinL., GaoZ., et al. (2015). miR-21 Modulates the immunoregulatory function of bone marrow mesenchymal stem cells through the PTEN/Akt/TGF-β1 pathway. Stem Cells, 33, 3281–3290.
52.
XuC., RenG., CaoG., ChenQ., ShouP., ZhengC., et al. (2013). miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2. J Biol Chem, 288, 11074–11079.
53.
YousefiF., ArabF.L., JaafariM.R., RastinM., TabasiN., HatamipourM., et al. (2019). Immunoregulatory, proliferative and anti-oxidant effects of nanocurcuminoids on adipose-derived mesenchymal stem cells. EXCLI J 18,405.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
